A5040283884- Diabetes Management and Research
- Diabetes Treatment and Management
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Diabetes and associated disorders
- Diabetes Management and Education
- Pancreatic function and diabetes
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Metabolism, Diabetes, and Cancer
- Chronic Disease Management Strategies
- Diet and metabolism studies
- Healthcare Policy and Management
- Resilience and Mental Health
- Assisted Reproductive Technology and Twin Pregnancy
- Nutrition, Genetics, and Disease
- Clinical practice guidelines implementation
- Child and Adolescent Psychosocial and Emotional Development
- Lipoproteins and Cardiovascular Health
- Diabetic Foot Ulcer Assessment and Management
- Grief, Bereavement, and Mental Health
- Migration, Health and Trauma
- Heart Rate Variability and Autonomic Control
- School Health and Nursing Education
- Health and Lifestyle Studies
- Health Systems, Economic Evaluations, Quality of Life
- Alcohol Consumption and Health Effects
The University of Texas Southwestern Medical Center
2014-2025
Parkland Health & Hospital System
2015-2025
Sanofi (United States)
2025
Southwestern Medical Center
2017-2022
University of Miami
2006-2021
Southwestern University
2021
Baylor Medical Center at Garland
2020
University of New Orleans
2019
Dallas Nephrology Associates
2018
Dallas County
2015
To examine patient and physician beliefs regarding insulin therapy the degree to which patients adhere their regimens.Internet survey of 1250 physicians (600 specialists, 650 primary care physicians) who treat with diabetes telephone 1530 insulin-treated (180 Type 1 diabetes, 1350 2 diabetes) in China, France, Japan, Germany, Spain, Turkey, UK or USA.One third (33.2%) reported omission/non-adherence at least day last month, an average 3.3 days. Three quarters (72.5%) report that typical does...
The requirement to inject current basal insulin analogs at a fixed time each day may complicate adherence and compromise glycemic control. This trial evaluated the efficacy safety of varying daily injection degludec (IDeg), an ultra-long-acting insulin.This 26-week, open-label, treat-to-target enrolled adults (≥18 years) with type 2 diabetes who were either naïve receiving oral antidiabetic drugs (OADs) (HbA(1c) = 7-11%) or previously on ± OAD(s) 7-10%). Participants randomized 1) once-daily...
Insulin degludec (IDeg) is a basal insulin that forms soluble multihexamers after subcutaneous injection, resulting in an ultra-long action profile. We assessed the efficacy and safety of IDeg formulations administered once daily combination with mealtime aspart people type 1 diabetes.In this 16-week, randomized, open-label trial, participants (mean: 45.8 years old, A1C 8.4%, fasting plasma glucose [FPG] 9.9 mmol/L, BMI 26.9 kg/m(2)) received injections IDeg(A) (600 μmol/L; n = 59), IDeg(B)...
Aim To examine factors associated with insulin injection omission/non‐adherence on a global basis. Methods Telephone survey of 1530 insulin‐treated adults self‐reported diabetes (110 type 1 and 1420 2) in China, France, Japan, Germany, Spain, Turkey, UK or USA . Participants had mean age ∼60 years, ∼15 years duration ∼9 treatment. Regression analysis assessed the independent associations (p < 0.05) country, participant characteristics treatment‐related beliefs/perceptions number days past...
The aim of this analysis is to determine the timing insulin initiation in routine clinical practice, especially relation glycaemic control and use oral antidiabetic drugs (OADs).Study Once Daily Levemir was a 24-week international observational study involving 10 countries which evaluated safety effectiveness initiating once-daily detemir people with type 2 diabetes mellitus (T2DM) being treated one or more OADs (clinical trial number NCT00825643 NCT00740519).A total 17 374 participants were...
Research has shown that getting to glycemic targets early on leads better outcomes in people with type 2 diabetes; yet, there been no improvement the attainment of A1C past decade. One reason is therapeutic inertia: lack timely adjustment treatment regimen when a person’s are not met. This article describes scope and priorities American Diabetes Association’s 3-year Overcoming Therapeutic Inertia Initiative. Its planned activities include publishing systematic review meta-analysis approaches...
People with type 2 diabetes (T2D) and glycated haemoglobin (HbA1c) ≥9% may benefit from fixed-ratio combination therapies such as iGlarLixi (insulin glargine 100 U/mL lixisenatide 33 μg/mL). Use of continuous glucose monitoring (CGM) is recommended, but data are lacking to assess the impact in individuals HbA1c ≥9%. Soli-CGM (NCT05114590) was a 16-week, multicentre, open-label study evaluating efficacy once-daily using blinded CGM-based metrics insulin-naive adults ≥9%-13% who were receiving...
The Predictable Results and Experience in Diabetes through Intensification Control to Target: An International Variability Evaluation 303 (PREDICTIVE 303) Study (n = 5604) evaluated the effectiveness of insulin detemir, a long-acting basal analogue, using simplified patient self-adjusted dosing algorithm (303 Algorithm group) compared with standard-of-care physician-driven adjustments (Standard-of-care predominantly primary care setting, over period 6 months. Insulin detemir was be started...
The purpose of this study was to identify patient beliefs as well clinical realities about insulin that may be barriers type 2 diabetes patients initiating treatment when recommended by their physician. This information then used develop a clinically relevant, cross-culturally valid education tool with the goal providing unbiased, medically informative statements addressing these barriers.Thirteen focus groups were conducted in five countries (Germany, Sweden, Netherlands, UK, and USA)...
Basal insulin (BI) plays an important role in treating type 2 diabetes (T2D), especially when oral antidiabetic (OAD) medications are insufficient for glycemic control. We conducted a retrospective, observational study using electronic medical records (EMR) data from the IBM® Explorys database to evaluate probability of achieving control over 24 months after BI initiation patients with T2D USA. A cohort 6597 who started following OAD(s) and had at least one valid glycated hemoglobin (HbA1c)...
The LIGHTNING study applied conventional and advanced analytic approaches to model, predict, compare hypoglycemia rates of people with type 2 diabetes (T2DM) on insulin glargine 300 U/ml (Gla-300) those first-generation (insulin 100 [Gla-100]; detemir [IDet]) or second-generation degludec [IDeg]) basal-insulin (BI) analogs, utilizing a large real-world database. Data were collected between 1 January 2007 31 March 2017 from the Optum Humedica US electronic health records [EHR]...
Objective: Predictable Results and Experience in Diabetes through Intensification Control to Target: an International Variability Evaluation (PREDICTIVETM) is a multi-national, open-label, prospective, observational study assessing the safety efficacy of insulin detemir clinical practice. This post hoc subanalysis evaluates insulin-naïve patients on oral antidiabetic drugs (OADs) who were initiated as basal therapy (± OADs). Methods: The European cohort PREDICTIVE currently includes 20,531...
This study assessed the efficacy and safety of once-daily insulin initiation using detemir (detemir) or glargine (glargine) added to existing metformin in type 2 diabetes (T2D).This 26-week, multinational, randomized, treat-to-target trial involved 457 insulin-naïve adults with T2D (HbA1c 7-9%). Detemir was current therapy [any second oral antidiabetic drug (OAD) discontinued] titrated a target fasting plasma glucose (FPG) ≤90 mg/dl (≤5.0 mmol/l). Primary endpoint change HbA1c.Mean (s.d.)...
Aim: In patients with type 2 diabetes mellitus (T2DM), combination therapy is usually required to optimize glucose metabolism as well help achieve aggressive targets for low‐density lipoprotein cholesterol (LDL‐C) and other lipid parameters associated cardiovascular risk. The thiazolidinediones (TZDs) are increasingly being used both their blood glucose‐lowering properties modest beneficial effects on triglycerides (TG) high‐density (HDL‐C). Ezetimibe, an intestinal absorption inhibitor, has...